Reference number : GC-2017-Q2-04359, amendment number : , agreement type : G, recipient legal name : Muench, Douglas (University of Calgary), recipient country : CA, recipient province : nan, recipient city : Alberta, recipient postal code : nan, program name english : Engage Grants for Universities, program name french : Subventions d'engagement partenarial pour les universités, program purpose english : Plant-based production of high-value therapeutic proteins, such as monoclonal antibodies, provides an_x000D_
attractive alternative to protein expression in mammalian cell systems. PlantForm Corporation is an established_x000D_
Canadian company that is supporting the lab of Dr. Douglas Muench at the University of Calgary on studies_x000D_
aimed at delivering an enhanced protein expression technology that can be universally applied to the expression_x000D_
of any high value protein of interest. One of PlantForm's most advanced products is a breast cancer therapeutic_x000D_
antibody. This grant will support a new collaborative research project that will test the hypothesis that a novel_x000D_
RNA-binding protein coupled to a translational enhancer can specifically elevate the expression of this_x000D_
antibody in a plant cell system. The Muench lab at the University of Calgary has recently characterized a_x000D_
sequence specific, high affinity RNA-binding protein (APUM23) from the model plant Arabidopsis. When_x000D_
coupled to a translational enhancer, APUM23 has the potential to significantly increase the synthesis of this_x000D_
therapeutic antibody. Success with this project will result in substantial revenue generation or cost savings to_x000D_
PlantForm, and will further establish the company as an industry leader in plant expression of therapeutic_x000D_
proteins., program purpose french : Plant-based production of high-value therapeutic proteins, such as monoclonal antibodies, provides an_x000D_
attractive alternative to protein expression in mammalian cell systems. PlantForm Corporation is an established_x000D_
Canadian company that is supporting the lab of Dr. Douglas Muench at the University of Calgary on studies_x000D_
aimed at delivering an enhanced protein expression technology that can be universally applied to the expression_x000D_
of any high value protein of interest. One of PlantForm's most advanced products is a breast cancer therapeutic_x000D_
antibody. This grant will support a new collaborative research project that will test the hypothesis that a novel_x000D_
RNA-binding protein coupled to a translational enhancer can specifically elevate the expression of this_x000D_
antibody in a plant cell system. The Muench lab at the University of Calgary has recently characterized a_x000D_
sequence specific, high affinity RNA-binding protein (APUM23) from the model plant Arabidopsis. When_x000D_
coupled to a translational enhancer, APUM23 has the potential to significantly increase the synthesis of this_x000D_
therapeutic antibody. Success with this project will result in substantial revenue generation or cost savings to_x000D_
PlantForm, and will further establish the company as an industry leader in plant expression of therapeutic_x000D_
proteins., agreement title english : Approach to enhance human antibody expression in plant cells, agreement title french : Approach to enhance human antibody expression in plant cells, agreement number : EGP, agreement value : 25000.0, agreement start date : 2017-09-20, agreement end date : nan, description english : nan, description french : nan, expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year (2017-2018 to 2018-2019)., additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier (2017-2018 à 2018-2019)., owner organization : nserc-crsng, owner organization title : Natural Sciences and Engineering Research Council of Canada | Conseil de recherches en sciences naturelles et en génie du Canada